Rituximab or Azathioprine for EGPA Maintenance? A French study has shown that rituximab is more effective than azathioprine at maintaining remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) on chronic prednisone. https://t.co/UrHqPBVibn https://t.co/cpusNcpYWd

Grappa Symposium: Leung Obesity in PsA - done deal @RheumNow #APLAR2026 https://t.co/3YQT4kiPer

AxSpA+rash vs Axial PsA Kishimoto : two phenotypes of the same disease and to maximise specificity Axis study - imaging criteria = AxSpA phenotype @RheumNow #APLAR2026 https://t.co/UYFnA3AyUM

An important and relevant reminder from @rheumarhyme on AI use @RheumNow #APLAR2026 https://t.co/7Ratb6aQOD

AI can be helpful in manuscript creation As the author: > always verify the draft - allow time to check > take full responsibility of the content - review and revise the final manuscript @RheumNow #APLAR2026 https://t.co/cQsEtDc7z1

Case quiz: 38F fever, tetraparesis, hallucinations, slurred speech. Low C3, ANA 1:100, WBC 26,320, normal CSF/Ca/PTH. CT: basal ganglia calcification. Dx? Answer: SLE with Fahr syndrome (focal NPSLE) plus urosepsis. Keep infection in rheum Ddx. P#325 #APLAR26 @RheumNow https://t.co/Gsb8dquwHL

Dr. Poddubny on AI & machine learning in SpA AI has enabled the analysis of large data sets offering a support for clinical decision-making. Future directions? Making scans faster leading to rapid analysis Challenge: access to large, high quality data @RheumNow #APLAR2026 https://t.co/UhdjSRXtOv

Better drugs only help if patients can get them. In an APLAR PsA registry, 43% of lowest-GDP patients had not reached MDA and were not on a biologic or targeted DMARD. Coverage, reimbursement and social support needed, not just science. P#242 #APLAR26 @RheumNow https://t.co/Rms4QsbcII

Raychaudhuri (day 2 plenary): Reconceptualizing cells as continuous states, not discrete types. In RA synovium, AMP defined six inflammation patterns (CTAPs) with key cell states, e.g. Tph in T+B. Do CTAPs respond to different targets? #APLAR26 @RheumNow https://t.co/jIosTqv5qZ

FDA has approved the IL-23 inhibitor tildrakizumab (Ilumya) use in adults with active psoriatic arthritis (PsA), expanding the interleukin indications beyond moderate-to-severe plaque psoriasis. (Based on INSPIRE-1/2; >800 adults, 52-week RCTs) https://t.co/tCKZQwf74A https://t.co/Qffr1ZAMd7

Takayasu Arteritis: Do TNFis or IL-6- inhibitors come out on top? The treatment of active TAK is imperative to quiet vascular inflammation and subsequently maintain vascular integrity while preventing vessel damage. https://t.co/J1EQHGzR5O https://t.co/i59kRGJCoK

Novartis announced the European Commission has approved secukinumab (Cosentyx) for use in adults w/ polymyalgia rheumatica, not responding to GCs. SEC is 1st IL-17A inhibitor approved in Europe for PMR https://t.co/ASTwbSrGr2 https://t.co/JCTszYa57m

JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory https://t.co/xTlr5lrwUz

"We really need to ask every patient who has psoriasis about their joints” – Dr. Ahmad Amin, Dermatologist Watch Dr. Amin and Dr. Saakshi Khattri discuss the link between skin and joints in PsA. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/rp2e5oknVF https://t.co/nf2vpvNJuV

Prof. Mease shares this important slide illustrating how excessive adipose tissue contributes to PsA dev’t 👇 Dysfunctional adipose tissue enables overall amplification of inflammation in obese pts with PsA @RheumNow #APLAR2026 https://t.co/1YtcqxM4B3